Business Description
Akari Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00972G1085
Share Class Description:
FRA:CLA: ADRDescription
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.25 | |||||
| Equity-to-Asset | -2.45 | |||||
| Debt-to-Equity | -0.15 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.9 | |||||
| 3-Year EPS without NRI Growth Rate | 45 | |||||
| 3-Year FCF Growth Rate | 32.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.89 | |||||
| 9-Day RSI | 26.97 | |||||
| 14-Day RSI | 28.94 | |||||
| 6-1 Month Momentum % | 19.77 | |||||
| 12-1 Month Momentum % | -20.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.29 | |||||
| Quick Ratio | 0.29 | |||||
| Cash Ratio | 0.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -51 | |||||
| Shareholder Yield % | -44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.94 | |||||
| EV-to-EBITDA | -0.94 | |||||
| EV-to-FCF | -1.78 | |||||
| Earnings Yield (Greenblatt) % | -105.8 | |||||
| FCF Yield % | -54.87 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Akari Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.532 | ||
| Beta | 0.72 | ||
| Volatility % | 99.2 | ||
| 14-Day RSI | 28.94 | ||
| 14-Day ATR (€) | 0.143057 | ||
| 20-Day SMA (€) | 1.75525 | ||
| 12-1 Month Momentum % | -20.16 | ||
| 52-Week Range (€) | 0.9 - 3.9 | ||
| Shares Outstanding (Mil) | 24.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Akari Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Akari Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Akari Therapeutics PLC Frequently Asked Questions
What is Akari Therapeutics PLC(FRA:CLA)'s stock price today?
The current price of FRA:CLA is €0.99. The 52 week high of FRA:CLA is €3.90 and 52 week low is €0.90.
When is next earnings date of Akari Therapeutics PLC(FRA:CLA)?
The next earnings date of Akari Therapeutics PLC(FRA:CLA) is .
Does Akari Therapeutics PLC(FRA:CLA) pay dividends? If so, how much?
Akari Therapeutics PLC(FRA:CLA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers